LIF has been identified as a novel predictive biomarker for resistance to PD1/PD-L1 blockade in non-small cell lung cancer (NSCLC) and bladder cancer patients, highlighting the potential of targeting LIF to enhance immune checkpoint blockade (ICB) therapy [19]. Here, LIF is linked to urinary bladder carcinoma.